Holland & Knight Advises Xenetic Biosciences on $4.5 Million Public Offering

MIAMI (October 21, 2025) – Holland & Knight represented Xenetic Biosciences Inc. (NASDAQ: XBIO) in connection with a $4.5 million underwritten public offering of common stock. Xenetic issued 735,000 shares of common stock at a price to the public of $6.12 per share. The transaction closed on October 14.

Proceeds from the transaction will be used for working capital and other general corporate purposes.

Headquartered in Framingham, Massachusetts, Xenetic Biosciences is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult-to-treat cancers.

Canaccord Genuity acted as the sole bookrunner for the offering.

Holland & Knight Partner Danielle Price (M&A) led the Firm's representation of Xenetic. She was assisted by Associates Lane Carson and Fay Shaulson (M&A) and Partner Robert Saunders (Financial Services).

More information on the transaction can be found here.